Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol.
CITATION STYLE
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., … Barter, P. (2010). Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. New England Journal of Medicine, 363(25), 2406–2415. https://doi.org/10.1056/nejmoa1009744
Mendeley helps you to discover research relevant for your work.